Loading...
Previous meta-analyses of long-term follow-up data from five large randomized trials of daily aspirin for prevention of vascular events showed that, compared with placebo or no treatment, aspirin lowered colon cancer incidence and mortality after 8 to 10 years and lowered mortality from other common solid cancers after 5 to 15 years (JW Gen Med Dec 29 2011). Now, these investigators have conducted two new meta-analyses of trials of aspirin for preventing vascular events: One, designed to assess the short-term effects of aspirin on cancer incidence and mortality, included in-trial data from 51 studies that involved more than 77,000 patients — and the other, aimed at studying aspirin's effects on risk for metastasis, included data from five U…